我國第一級、第二級管制藥品2008－2017年銷售及使用趨勢分析   全文下載

Trends in the Consumption of Schedule I and Schedule II Controlled Drugs in Taiwan from 2008 to 2017

我國第一級、第二級管制藥品常做為癌症疼痛與非癌症的慢性疼痛治療，隨著國人對於積極疼痛治療觀念的增進，其使用量也逐年上升；臨床上，醫師對於處方管制藥品的多樣性需求也持續增加。本研究之目的為藉由分析製藥工廠的銷售資料及全民健康保險資料庫使用資料，以了解第一級、第二級管制藥品最新的銷售及使用趨勢。結果顯示，整體銷售量從2008年515.5 S－DDD／m／d（每百萬人口每日定義劑量）成長至2017年1,375.6 S－DDD／m／d，約增加167％；整體健保使用量從2008年446.2 S－DDD／m／d至2016年568.1 S－DDD／m／d，約增加27.3％。近年新引進的藥品如oxycodone口服劑型使用量成長快速，應持續監測其使用趨勢、成癮與濫用情形、以及藥品不良反應發生風險等，以持續提供符合臨床需求的藥品及維護病人用藥安全。

Only a few Schedule I and Schedule II controlled drugs are approved for medical use in the management of cancer pain and chronic non-cancer pain in Taiwan. As people are better educated in the area of pain management, the consumption of schedule I and II controlled drugs have increased over the past years, and there are more diverse requirements by physicians for clinical use in Taiwan. The aims of this study is to investigate the latest trend in the consumption and utilization pattern of schedule I and II controlled drugs by analyzing the data from sales database of the pharmaceutical plant of TFDA and the National Health Insurance Research Database. Our study shows that the overall sales increased by 167% from 515.5 S-DDD/m/d (Defined Daily Dose for Statistical Purposes per million person per day) to 1,375.6 S-DDD/m/d between 2008 and 2017. The drug consumption of those drugs which were reimbursed by National Health Insurance increased by 27.3% from 446.2 S-DDD/m/d to 568.1 S-DDD/m/d during 2008 to 2016. Particularly, the use of newly introduced drugs such as oxycodone has grown rapidly in recent years. It is recommended that the trend of opioid consumption, addiction, abuse, and the risk of side effects should be continuously monitored.